<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60255">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723735</url>
  </required_header>
  <id_info>
    <org_study_id>PKD12910</org_study_id>
    <secondary_id>U1111-1131-3203</secondary_id>
    <nct_id>NCT01723735</nct_id>
  </id_info>
  <brief_title>Effect of Alirocumab SAR236553 (REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects</brief_title>
  <official_title>A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the pharmacodynamic profile of alirocumab SAR236553 (REGN727) administered either
      alone or on top of ezetimibe or fenofibrate, based on low-density lipoprotein -cholesterol
      (LDL-C).

      Secondary Objectives:

      To assess the pharmacodynamic profile of alirocumab SAR236553 (REGN727) administered either
      alone or on top of ezetimibe or fenofibrate,  based on other lipid parameters.

      To assess the pharmacokinetic profile of alirocumab SAR236553 (REGN727) administered either
      alone or on top of ezetimibe or fenofibrate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration of the study per subject (excluding screening) is about 22 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Assessment of the effect of alirocumab SAR236553 (REGN727) on LDL-C</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the pharmacodynamic profile of alirocumab SAR236553 (REGN727)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics:  Assessment of serum concentrations of alirocumab SAR236553 (REGN727)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics:  Assessment of serum concentrations of PCSK9</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ ezetimibe placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of ezetimibe placebo and injections of alirocumab SAR236553 (REGN727) through subcutaneous (SC) administration
alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of ezetimibe and injections of alirocumab SAR236553 (REGN727) through subcutaneous (SC) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of fenofibrate and injections of alirocumab SAR236553 (REGN727) through subcutaneous (SC) administration - Type: Experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab SAR236553 (REGN727)</intervention_name>
    <description>Pharmaceutical form:Solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ ezetimibe</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ ezetimibe placebo</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>Pharmaceutical form:overencapsulated tablet Route of administration: oral</description>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ ezetimibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe placebo</intervention_name>
    <description>Pharmaceutical form:capsule Route of administration: oral</description>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ ezetimibe placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>alirocumab SAR236553 (REGN727)+ fenofibrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Healthy male /or female subjects,

          -  aged 18 to 65 years old,

          -  with LDL-C &gt; 130 mg/dL

          -  not receiving lipid lowering therapy.

        Exclusion criteria:

          -  Healthy subjects with history or presence of clinically relevant illness.

          -  Subjects currently taking statins, ezetimibe or fenofibrate.

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Rueil Malmaison</city>
        <zip>92502</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
